Efprezimod alfa
- Generic Name
- Efprezimod alfa
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- FN12T66RMN
- Background
CD24Fc is a biological immunomodulator originally developed to address graft-versus-host disease in stem cell transplantation in leukemia patients.
- Associated Conditions
- -
- Associated Therapies
- -
Efprezimod Alfa (CD24Fc, MK-7110) as a Non-antiviral Immunomodulator in COVID-19 Treatment (MK-7110-007)
- Conditions
- Interventions
- First Posted Date
- 2020-03-20
- Last Posted Date
- 2023-02-08
- Target Recruit Count
- 234
- Registration Number
- NCT04317040
- Locations
- ๐บ๐ธ
Baptist Health Research Institute, Jacksonville, Florida, United States
๐บ๐ธInstitute of Human Virology, University of Maryland Baltimore, Baltimore, Maryland, United States
๐บ๐ธCooper University Hospital, Camden, New Jersey, United States
Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005)
- First Posted Date
- 2019-09-19
- Last Posted Date
- 2023-02-08
- Target Recruit Count
- 11
- Registration Number
- NCT04095858
- Locations
- ๐บ๐ธ
Abramson Cancer Center of the University of Pennsylvania ( Site 0309), Philadelphia, Pennsylvania, United States
๐บ๐ธCity of Hope ( Site 0302), Duarte, California, United States
๐บ๐ธThe University of Chicago Medical Center ( Site 0306), Chicago, Illinois, United States
Phase II Trial of Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft-Versus-Host Disease (GVHD) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-002)
- Conditions
- Interventions
- First Posted Date
- 2016-01-26
- Last Posted Date
- 2024-01-23
- Target Recruit Count
- 44
- Registration Number
- NCT02663622
- Locations
- ๐บ๐ธ
The University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
๐บ๐ธIndiana University School of Medicine, Indianapolis, Indiana, United States
๐บ๐ธOhio State University, Columbus, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.